var docs;if (!docs) docs =[]; docs["105"]={"10500":"<p><b>Title</b> Ajmaline / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased ajmaline effects and toxicities if combined with moderate CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 4 healthy volunteers, the strong CYP2D6 inhibitor quinidine (100 mg x 1 followed by 200 mg x1 12 hours later) increased the ajmaline (50 mg single dose) AUC and maximum serum concentration 22-fold and 7.8-fold, respectively.<sup>1</sup><br><br>Ajmaline product labeling states that because ajmaline is metabolized by CYP2D6, concomitant use with CYP2D6 inhibitors may increase ajmaline concentrations and effects.<sup>2</sup><br><br>Although not fully investigated, the likely mechanism of this interaction is inhibition of CYP2D6, an enzyme responsible for ajmaline metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hori R, Okumura K, Inui K, et al. Quinidine-induced rise in ajmaline plasma concentrations. <i>J Pharm Pharmacol</i>. 1984;36(3):202-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6144760\">[PubMed 6144760]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p>3. Koppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. <i>Eur J Drug Metab Pharmacokinet</i>. 1989;14(4):309-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2633926\">[PubMed 2633926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10501":"<p><b>Title</b> Ajmaline / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> QuiNIDine may enhance the arrhythmogenic effect of Ajmaline. QuiNIDine may increase the serum concentration of Ajmaline. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the concomitant use of quinidine and ajmaline.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 4 healthy volunteers, quinidine (100 mg x 1 followed by 200 mg x1 12 hours later) increased the ajmaline (50 mg single dose) AUC and maximum serum concentration 22-fold and 7.8-fold, respectively.<sup>1</sup> The mechanism of the pharmacokinetic interaction is likely inhibition of CYP2D6, an enzyme responsible for ajmaline metabolism.<sup>2,3</sup><br><br>In addition to the pharmacokinetic interaction between quinidine and ajmaline, ajmaline product labeling states that ajmaline should not be combined with other class Ia antiarrhythmics (ie, quinidine) due to the risk of additive QTc prolongation and severe cardiac toxicites.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hori R, Okumura K, Inui K, et al. Quinidine-induced rise in ajmaline plasma concentrations. <i>J Pharm Pharmacol</i>. 1984;36(3):202-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6144760\">[PubMed 6144760]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p>3. Koppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. <i>Eur J Drug Metab Pharmacokinet</i>. 1989;14(4):309-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2633926\">[PubMed 2633926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10502":"<p><b>Title</b> Travelers' Diarrhea and Cholera Vaccine / Vedolizumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Vedolizumab may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer the oral travelers' diarrhea and cholera vaccine prior to initiation of therapy with vedolizumab. If travelers' diarrhea and cholera vaccine is administered during therapy with vedolizumab, monitor for decreased effectiveness of the vaccine.</p> \n<p><b>Discussion</b> In a clinical study, healthy participants (N=123) were randomized to vedolizumab (750 mg) or placebo.<sup>1,2</sup> After 4 days, all participants received the intramuscular hepatitis B vaccine sequence (on days 4, 32, and 60) and the oral cholera vaccine sequence (on days 4 and 18). Seroconversion rates for the hepatitis B vaccine did not differ between vedolizumab or placebo groups. Response rates to the oral cholera vaccine were 82.5% in vedolizumab treated patients compared with 96.8% in placebo treated patients. Vedolizumab did not meet the prespecified criteria for noninferiority compared with placebo. Vedolizumab prescribing information suggests that patients should be brought up to date with all immunizations prior to initiation of treatment with vedolizumab.<sup>1</sup><br><br>The mechanism for the reduced response rate to the oral cholera vaccine, but not the intramuscular hepatitis B vaccine, is hypothesized to be that vedolizumab may selectively attenuate the gastrointestinal tract immune response. The impact of vedolizumab on other oral or nasal vaccines is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Entyvio (vedolizumab) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; May 2014.</p>\n<p>2. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i>. 2015;64(1):77-83 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24763133\">[PubMed 24763133]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10505":"<p><b>Title</b> Alitretinoin (Systemic) / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C8 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C8 inhibitor.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> Product labeling for alitretinoin states that a dose reduction of alitretinoin should be considered with use of a strong CYP2C8 inhibitor.<sup>1</sup> Data concerning such a combination are not available, but in vitro data suggest that CYP2C8, CYP2C9, and CYP3A4 all contribute to alitretinoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Toctino (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10507":"<p><b>Title</b> Estrogen Derivatives / Pomalidomide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling specifically recommends avoiding use of hormonal contraceptives and recommends caution with use of hormone replacement therapy. US labeling does not contain these specicfic warnings.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pomalidomide may enhance the thrombogenic effect of Estrogen Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of hormone replacement therapy and states that the use of hormonal contraceptives are not recommended for patients receiving pomalidomide plus dexamethasone. The US labeling for pomalidomide does not contain these specific recommendations. Advise any patients who are using such a combination of the possible increased risk for venous and arterial thromboembolic events. Monitor closely for any signs or symptoms of thromboembolic events.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of hormone replacement therapy and states that the use of hormonal contraceptives are not recommended for patients receiving pomalidomide plus dexamethasone.<sup>1</sup> However, the US labeling for pomalidomide does not contain these specific recommendations.<sup>2</sup> These recommendations are related to the risk for thromboembolic events association with use of pomalidomide plus dexamethasone. According to data in the pomalidomide labeling, thromboembolic events were reported in 8% of patients receiving pomalidomide plus low-dose dexamethasone and in 3.3% of patients receiving pomalidomide plus high-dose dexamethasone in a trial of patients who were all receiving anticoagulant therapy.<sup>2</sup><br><br>This warning is likely due to the potential for estrogens and progestins to increase the risk for thromboembolic events. Both US and Canadian labeling for pomalidomide do contain a warning that patients with other known risk factors for thromboembolic events may be at higher risk during pomalidomide therapy and that clinicians should try to minimize any modifiable risk factors.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pomalyst (polamidomide) [product monograph]. Mississauga, Ontario, Canada: Celgene Inc.; April 2016.</p>\n<p>2. Pomalyst (polamidomide) [prescribing information]. Summit, NJ: Celgene Corporation; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10508":"<p><b>Title</b> Pomalidomide / Progestins</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling specifically recommends avoiding use of hormonal contraceptives and recommends caution with use of hormone replacement therapy. US labeling does not contain these specicfic warnings.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Progestins may enhance the thrombogenic effect of Pomalidomide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of hormone replacement therapy and states that the use of hormonal contraceptives are not recommended for patients receiving pomalidomide plus dexamethasone. The US labeling for pomalidomide does not contain these specific recommendations. Advise any patients who are using such a combination of the possible increased risk for venous and arterial thromboembolic events. Monitor closely for any signs or symptoms of thromboembolic events.</p>\n<div>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of hormone replacement therapy and states that the use of hormonal contraceptives are not recommended for patients receiving pomalidomide plus dexamethasone.<sup>1</sup> However, the US labeling for pomalidomide does not contain these specific recommendations.<sup>2</sup> These recommendations are related to the risk for thromboembolic events association with use of pomalidomide plus dexamethasone. According to data in the pomalidomide labeling, thromboembolic events were reported in 8% of patients receiving pomalidomide plus low-dose dexamethasone and in 3.3% of patients receiving pomalidomide plus high-dose dexamethasone in a trial of patients who were all receiving anticoagulant therapy.<sup>2</sup><br><br>This warning is likely due to the potential for estrogens and progestins to increase the risk for thromboembolic events. Both US and Canadian labeling for pomalidomide do contain a warning that patients with other known risk factors for thromboembolic events may be at higher risk during pomalidomide therapy and that clinicians should try to minimize any modifiable risk factors.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pomalyst (polamidomide) [product monograph]. Mississauga, Ontario, Canada: Celgene Inc.; April 2016.</p>\n<p>2. Pomalyst (polamidomide) [prescribing information]. Summit, NJ: Celgene Corporation; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10509":"<p><b>Title</b> Pomalidomide / Erythropoiesis-Stimulating Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of erythropoietic agents in patients receiving pomalidomide plus dexamethasone. The US labeling for pomalidomide does not contain this specific recommendation. Advise any patients who are using such a combination of the possible increased risk for venous and arterial thromboembolic events. Monitor closely for any signs or symptoms of thromboembolic events.</p>\n<div>\n <p><b>Erythropoiesis-Stimulating Agents Interacting Members</b> Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin Lambda, Epoetin Zeta, Methoxy Polyethylene Glycol-Epoetin Beta</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for pomalidomide recommends caution with concurrent use of erythropoietic agents in patients receiving pomalidomide plus dexamethasone.<sup>1</sup> However, the US labeling for pomalidomide does not contain this specific recommendation.<sup>2</sup> This recommendation is related to the risk for thromboembolic events association with use of pomalidomide plus dexamethasone. According to data in the pomalidomide labeling, thromboembolic events were reported in 8% of patients receiving pomalidomide plus low-dose dexamethasone and in 3.3% of patients receiving pomalidomide plus high-dose dexamethasone in a trial of patients who were all receiving anticoagulant therapy.<sup>2</sup><br><br>This warning is likely due to the potential for erythropoietic agents to increase the risk for thromboembolic events. Both US and Canadian labeling for pomalidomide do contain a warning that patients with other known risk factors for thromboembolic events may be at higher risk during pomalidomide therapy and that clinicians should try to minimize any modifiable risk factors.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pomalyst (polamidomide) [product monograph]. Mississauga, Ontario, Canada: Celgene Inc.; April 2016.</p>\n<p>2. Pomalyst (polamidomide) [prescribing information]. Summit, NJ: Celgene Corporation; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10510":"<p><b>Title</b> Benoxinate / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to benoxinate administration closely, and advise patients that the effects of the benoxinate may be prolonged if used together with an acetylcholinesterase inhibitor.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n</div> \n<p><b>Discussion</b> Benoxinate labeling states that acetylcholinesterase inhibitors may inhibit the metabolism of ester-type local anesthetics, such as benoxinate, possibly resulting in prolonged benoxinate effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oxybuprocaine (benoxinate) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Ltd; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10512":"<p><b>Title</b> Blood Pressure Lowering Agents / Naftopidil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Naftopidil may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients of the possibility for hypotension, dizziness, and related symptoms with use of this combination. Monitor patient response to therapy closely.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The naftopidil labeling states that concurrent use of blood pressure lowering agents may result in an increased risk for hypotension and related symptoms due to enhanced vasorelaxation resulting from the combination.<sup>1</sup> Naftopidil is an alpha-1 inhibitor with a reported incidence of hypotension and dizziness of 0.1% to 1%.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Flivas (naftopidil) [summary of product characteristics]. Tokyo, Japan: Asahi Kasei Pharma Corporation; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10531":"<p><b>Title</b> Telithromycin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Telithromycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of telithromycin adverse effects if used together with a strong CYP3A4 inhibitor. Alternative agents may need to be considered, particularly in patients with severe renal or hepatic impairment. Some specific strong CYP3A4 inhibitors, such as itraconazole and ketoconazole should be avoided with telithromcyin. Since telithromycin is a strong CYP3A4 inhibitor itself, some other combinations, such as with ceritinib, should be avoided when possible due to telithromycin's CYP3A4 inhibition.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The telithromycin maximum serum concentration (Cmax) and AUC were increased by an average of 51% and 95%, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> Similarly, the telithromycin AUC was an average of 54% higher with use of the strong CYP3A inhibitor itraconazole.<sup>2</sup> The telithromycin prescribing information cautions that use with CYP3A4 inhibitors may increase or prolong both the therapeutic and adverse effects of telithromycin. The labeling also specifies that use with the specific CYP3A4 strong inhibitors itraconazole and ketoconazole should be avoided in conjunction with telithromycin as they have been shown to increase telithromycin pharmacokinetic parameters significantly.<sup>1</sup> Dosage adjustments or avoidance of concomitant use with other strong CYP3A4 inhibitors may, therefore, be warranted.<br><br>Conversely, other results described in the literature have shown telithromycin to be well-tolerated with concomitant administration with ketoconazole. In a study of patients older than 60 years-of-age with renal impairment (n=32), the Cmax and AUC of telithromycin increased by 1.6- and 2.7-fold, respectively, vs. healthy subjects with ketoconazole, but QTc intervals were within normal ranges and telithromycin was well-tolerated despite higher plasma concentrations.<sup>3</sup> Clarithromycin was used as a comparator in this study, where patients also tolerated higher plasma concentrations of telithromycin (Cmax 2.2-fold, AUC 3.3-fold) when administered with clarithromycin. Patients also did not experience QTc interval prolongation. Product labeling for itraconazole and ketoconazole generally only recommend clinical monitoring when using either of these agents with telithromycin,<sup>4,5</sup> although the itraconazole label does specifically recommend avoiding concomitant use in patients with severe renal and hepatic impairment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ; Sanofi-Aventis U.S. LLC; October 2015.</p>\n<p>2. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. <i>Pharmacotherapy</i>. 2005;25(1):42-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767219\">[PubMed 15767219]</a></p>\n<p>3. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. <i>Int J Clin Pharmacol Ther</i>. 2005;43(3):123-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15792396\">[PubMed 15792396]</a></p>\n<p>4. Nizoral (ketoconazole) [prescribing information]. Titusville, NJ; Janssen Pharmaceuticals, Inc.; February 2014.</p>\n<p>5. Sporanox (itraconazole) [prescribing information]. Titusville, NJ; Janssen Pharmaceuticals, Inc.; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10532":"<p><b>Title</b> Warfarin / Salicylates (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates (Topical) may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (eg, increased INR, bleeding) if topical salicylates are used in patients taking warfarin.</p>\n<div>\n <p><b>Salicylates (Topical) Interacting Members</b> Diethylamine Salicylate, Methyl Salicylate, Trolamine</p>\n</div> \n<p><b>Discussion</b> In a retrospective study of patients stable on long-term warfarin therapy, 11 patients were identified that experienced an elevated INR after initiation of topical methyl salicylate.<sup>1</sup> Mean INR increased from 2.3 to 4.5 and all patients had detectable serum salicylate levels.<sup>1</sup> Two patients developed bruising and 1 patient experienced gastrointestinal bleeding.<sup>1</sup> Six weeks after discontinuation of methyl salicylate, INRs had returned to the therapeutic range in all patients and serum salicylate levels were no longer detectable.<sup>1</sup> Numerous other reports describe INR elevations and bleeding events after the addition of methyl salicylate or trolamine to stable warfarin therapy.<sup>2,3,4,5,6,7,8</sup><br><br>Diethylamine salicylate prescribing information states that since there have been reports that topical salicylates can potentiate the anticoagulant effects of warfarin, caution and increased monitoring are recommended if these agents are combined.<sup>9</sup><br><br>The mechanism of this interaction has not been fully investigated, but salicylates may inhibit the synthesis of vitamin K-dependent clotting factors and/or displace warfarin from protein binding sites.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yip AS, Chow WH, Tai YT, Cheung KL. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. <i>Postgrad Med J</i>. 1990;66(775):367-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2371186\">[PubMed 2371186]</a></p>\n<p>2. Chan TY. Life-threatening retroperitoneal bleeding due to warfarin-drug interactions. <i>Pharmacoepidemiol Drug Saf</i>. 2009;18(5):420-422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19283775\">[PubMed 19283775]</a></p>\n<p>3. Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. <i>Ann Pharmacother</i>. 2000;34(6):729-733. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10860133\">[PubMed 10860133]</a></p>\n<p>4. Chan TY. Drug interactions as a cause of overanticoagulation and bleedings in Chinese patients receiving warfarin. <i>Int J Clin Pharmacol Ther</i>. 1998;36(7):403-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9707357\">[PubMed 9707357]</a></p>\n<p>5. Ramanathan M. Warfarin-topical salicylate interactions: case reports. <i>Med J Malaysia</i>. 1995;50(3):278-279. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8926909\">[PubMed 8926909]</a></p>\n<p>6. Tam LS, Chan TY, Leung WK, Critchley JA. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. <i>Aust N Z J Med</i>. 1995;25(3):258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7487701\">[PubMed 7487701]</a></p>\n<p>7. Chow WH, Cheung KL, Ling HM, See T. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. <i>J R Soc Med</i>. 1989;82(8):501-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2778785\">[PubMed 2778785]</a> </p>\n<p>8. Littleton F Jr. Warfarin and topical salicylates. <i>JAMA</i>. 1990;263(21):2888. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338749\">[PubMed 2338749]</a></p>\n<p>9. Algesal (diethylamine salicylate) [summary of product characteristics]. Huddersfield, UK: Thomton &amp; Ross Limited; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10533":"<p><b>Title</b> Methotrexate / Diethylamine Salicylate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diethylamine Salicylate may increase the serum concentration of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased methotrexate effects/toxicities if combined with diethylamine salicylate.</p> \n<p><b>Discussion</b> Serum concentrations, and associated toxicity, of methotrexate appear to be increased by concomitant salicylate administration. The effect of salicylates on single doses of methotrexate (10 mg) is relatively small (increase AUC 28%; decrease clearance 16%).<sup>1</sup> Similar effects are seen with aminosalicylate sodium and choline magnesium trisalicylate.<sup>2,3</sup> Higher doses of methotrexate (eg, 50 mg/day for 10 days) administered with salicylates have resulted in lethal pancytopenia.<sup>4</sup> The severity of the interaction appears to worsen with increasing doses of methotrexate and/or salicylates.<br><br>No reports of methotrexate toxicity have been described when combined with diethylamine salicylate. However, product labeling states that after topical application of diethylamine salicylate, small amounts of salicylic acid are detectable in plasma, and may lead to increased methotrexate serum levels and toxicity.<sup>5</sup> <br><br>The mechanism(s) of these interactions might be multifold. Salicylates might compete with methotrexate for renal tubular secretion. Due to their inhibition of prostaglandin synthesis, salicylates might also reduce renal perfusion, and subsequently reduce methotrexate elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. <i>Arthritis Rheum</i>. 1991;34(12):1514-1520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1747136\">[PubMed 1747136]</a></p>\n<p>2. Maier WP, Leon-Perez R, Miller SB. Pneumonitis during low-dose methotrexate therapy. <i>Arch Intern Med</i>. 1986;146(3):602-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3954536\">[PubMed 3954536]</a></p>\n<p>3. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. <i>Eur J Clin Pharmacol</i>. 1990;42(2):121-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618240\">[PubMed 1618240]</a></p>\n<p>4. Mandel MA. The synergistic effect of salicylates on methotrexate toxicity. <i>Plast Reconstr Surg</i>. 1976;57(6):733-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1273152\">[PubMed 1273152]</a></p>\n<p>5. Algesal (diethylamine salicylate) [summary of product characteristics]. Huddersfield, UK: Thomton &amp; Ross Limited; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10534":"<p><b>Title</b> Aminoglycosides / Neomycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Neomycin (Topical) may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Labeling for some topical neomycin products states that, if absorbed, they may enhance nephrotoxic effects of other aminoglycosides.<sup>1</sup> Absorption of neomycin from topical formulations is typically poor, but may be increased under some circumstances (eg, large treatment area, more frequent application, compromised skin barrier).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baneocin (bacitracin and neomycin) [product information]. Singapore: Sandoz; received June 9, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10535":"<p><b>Title</b> Cephalosporins / Neomycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Neomycin (Topical) may enhance the nephrotoxic effect of Cephalosporins. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Cephalosporins Interacting Members</b> Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefditoren, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Flomoxef</p>\n</div> \n<p><b>Discussion</b> Labeling for some topical neomycin products states that, if absorbed, they may enhance nephrotoxic effects of cephalosporins.<sup>1</sup> Absorption of neomycin from topical formulations is typically poor, but may be increased under some circumstances (eg, large treatment area, more frequent application, compromised skin barrier).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baneocin (bacitracin and neomycin) [product information]. Singapore: Sandoz; received June 9, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10536":"<p><b>Title</b> Loop Diuretics / Neomycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Neomycin (Topical) may enhance the adverse/toxic effect of Loop Diuretics. Specifically, nephrotoxicity and ototoxicity risk may be enhanced. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Labeling for some topical neomycin products states that, if absorbed, they may enhance nephrotoxic and ototoxic effects of loop diuretics.<sup>1</sup> Absorption of neomycin from topical formulations is typically poor, but may be increased under some circumstances (eg, large treatment area, more frequent application, compromised skin barrier).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baneocin (bacitracin and neomycin) [product information]. Singapore: Sandoz; received June 9, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10537":"<p><b>Title</b> Neuromuscular-Blocking Agents / Neomycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Neomycin (Topical) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Labeling for some topical neomycin products states that, if absorbed, they may enhance neuromuscular-blocking effects of neuromuscular-blocking agents.<sup>1</sup> Absorption of neomycin from topical formulations is typically poor, but may be increased under some circumstances (eg, large treatment area, more frequent application, compromised skin barrier).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baneocin (bacitracin and neomycin) [product information]. Singapore: Sandoz; received June 9, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10538":"<p><b>Title</b> Regorafenib / Neomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neomycin may decrease serum concentrations of the active metabolite(s) of Regorafenib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of diminished response to regorafenib if used together with, or possibly immediately after, oral neomycin therapy.</p> \n<p><b>Discussion</b> The AUC of the M-2 and M-5 regorafenib metabolites was an average of 76% and 86% lower, respectively, when regorafenib was administered on day 5 of neomycin administration (1 g three times/day) in a study of 27 healthy male volunteers.<sup>1</sup> The M-2 and M-5 metabolites have been shown to have similar pharmacological activity as regorafenib, and both also reportedly have similar steady-state concentrations as regorafenib, so may contribute to the overall response to regorafenib therapy.<br><br>The specific mechanism of this interaction is likely impaired enterohepatic recycling of the active M-2 and M-5 metabolites. Neomycin's intestinal antibacterial activity resulting in less bacterial production of glucuronidase would be expected to lead to less liberation of the M-2 and M-5 metabolites from their respective glucuronide conjugates that are excreted via the bile into the gastrointestinal tract. Whether other antibacterials with significant activity against the normal flora in the gastrointestinal tract would have a similar interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stivarga (regorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10539":"<p><b>Title</b> Lactobacillus and Estriol / Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effectiveness of the lactobacillus and estriol tablet if used while patients are taking antibiotics.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Oral Inhalation), Aztreonam (Systemic), Bacampicillin, Bacitracin (Systemic), Bedaquiline, Capreomycin, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Fidaxomicin, Flomoxef, Flucloxacillin, Fosfomycin, Framycetin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Gentian Violet, Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Neomycin, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Polymyxin B, Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, RifAXIMin, Roxithromycin, Secnidazole, Sparfloxacin, Spiramycin, Streptomycin, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Bacitracin (Ophthalmic), Bacitracin (Topical), Benzoin, Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), Hexachlorophene, Mafenide, MetroNIDAZOLE (Topical), Mupirocin, Nitrofurazone, Oxychlorosene, Ozenoxacin, Pentamidine (Oral Inhalation), Povidone-Iodine (Topical), Silver Nitrate, Silver Sulfadiazine, Sulfacetamide (Ophthalmic), Sulfacetamide (Topical), Taurolidine, Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> Product labeling for the lactobacillus and estriol tablet states that since <i>Lactobacilli</i> bacteria are sensitive to numerous antibiotic agents, simultaneous treatment with antibiotics could lead to a reduction in the efficacy of the lactobacillus and estriol tablet.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gynoflor (estriol and lactobacillus) vaginal tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199604597. Accessed June 15, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10540":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Naftazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Naftazone may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased bleeding if naftazone is combined with nonsteroidal anti-inflammatory drugs (NSAIDs).</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> One case report describes a 26-year-old man who experienced a left hemothorax requiring surgical intervention (bullectomy, wedge resection, hematoma evacuation) after a chest tube was inserted for spontaneous pneumothorax.<sup>1,2</sup> A thoracic epidural catheter was placed for patient-controlled analgesia (ropivacaine and fentanyl) and used on postoperative days (POD) 0 to 3.<sup>1,2</sup> On POD 1 mefenamic acid (250 mg three times daily) was initiated, on POD 3 the epidural catheter was removed, and on POD 4 ketorolac (30 mg single IV dose) was administered. On POD 5, after complaining of weakness and numbness in his lower extremities, the patient was diagnosed with a massive anterior epidural hematoma that was compressing the spinal cord. A review of his home medications found that he had been taking naftazone (10 mg three times daily) for seven days prior to presentation. After surgical hematoma evacuation and discontinuation of all NSAIDs, the patient made a full recovery.<sup>1,2</sup><br><br>While the cause of the epidural hematoma is likely multifactorial, it was hypothesized that the antiplatelet effects of naftazone<sup>3</sup> combined with the antiplatelet effects of the NSAIDs (mefenamic acid and ketorolac) may have contributed to this adverse bleeding event.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yoon KW, Song JG, Ryu JW, Kim YJ. Whole spontaneous spinal epidural hematoma. <i>Asian Spine J</i>. 2014;8(3):361-364. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24967052\">[PubMed 24967052]</a></p>\n<p>2. Jeon DG, Song JG, Kim SK, Kim J. Epidural hematoma after thoracic epidural analgesia in a patient treated with ketorolac, mefenamic acid, and naftazone: a case report. <i>Korean J Anesthesiol</i>. 2014;66(3):240-243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24729848\">[PubMed 24729848]</a></p>\n<p>3. Durand P, Bloy C, Peltier-Pujol F, Blache D. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone. <i>J Pharm Pharmacol</i>. 1996;48(6):566-572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8832488\">[PubMed 8832488]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10541":"<p><b>Title</b> Calcifediol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased calcifediol effects (eg, hypercalcemia, subtherapeutic intact PTH, elevated 25-hydroxyvitamin D levels) if combined with a strong CYP3A4 inhibitor. Reduced calcifediol doses may be required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Calcifediol prescribing information states that strong CYP3A4 inhibitors may also inhibit enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1) and may alter serum levels of calcifediol.<sup>1</sup> Dose adjustment of calcifediol may be required, and serum 25-hydroxyvitamin D, intact PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10542":"<p><b>Title</b> Calcifediol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased calcifediol effects (eg, elevated intact PTH, subtherapeutic 25-hydroxyvitamin D levels) if combined with a strong CYP3A4 inducer. Increased calcifediol doses may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Calcifediol prescribing information states that phenobarbital, other anticonvulsants, or strong CYP3A4 inducers may reduce the half-life of calcifediol.<sup>1</sup> Dose adjustment of calcifediol may be required, and serum total 25-hydroxyvitamin D, intact PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with strong CYP3A4 inducers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10543":"<p><b>Title</b> Voriconazole / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Voriconazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased voriconazole serum concentrations if voriconazole is combined with dexamethasone. Increased voriconazole doses may be required.</p> \n<p><b>Discussion</b> Two retrospective cohort studies of voriconazole-treated patients found that corticosteroid use, including dexamethasone, was associated with an increased risk of subtherapeutic voriconazole levels.<sup>1,2</sup> A case report describes an 84-year-old man who experienced clinical disease progression and subtherapeutic voriconazole trough levels (1.1 mcg/ml) 20 days into treatment with voriconazole (200 mg twice daily) and dexamethasone (4 mg every 8 hours) for cerebral phaehyphomycosis.<sup>3</sup> Voriconazole trough levels continued to decrease despite voriconazole dose increases and a change from oral to intravenous administration. Voriconazole trough levels did not reach the therapeutic range until dexamethasone was discontinued.<sup>3</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but dexamethasone-mediated induction of CYP enzymes involved in voriconazole metabolism (eg, CYP3A4, CYP2C9, CYP2C19) may play a role.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cojutti P, Candoni A, Forghieri F, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450(CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. <i>Basic Clin Pharmacol Toxicol</i>. 2016;118(6):474-479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26572687\">[PubMed 26572687]</a></p>\n<p>2. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. <i>Antimicrob Agents Chemother</i>. 2012;56(9):4793-4799. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22751544\">[PubMed 22751544]</a></p>\n<p>3. Wallace KL, Filipek RL, La Hoz RM, Williamson JC. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature [published online May 20, 2016]. <i>J Clin Pharm Ther</i>. Doi: 10.1111/jcpt.12401 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27207573\">[PubMed 27207573]</a></p>\n<p>4. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. <i>Drug Metab Dispos</i>. 2001;29(3):242-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11181490\">[PubMed 11181490]</a></p>\n<p>5. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. <i>J Pharmacol Exp Ther</i>. 2002;302(2):475-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12130704\">[PubMed 12130704]</a></p>\n<p>6. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10544":"<p><b>Title</b> SUNItinib / NiCARdipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> NiCARdipine may increase the serum concentration of SUNItinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased sunitinib concentrations and effects if combined with nicardipine.</p> \n<p><b>Discussion</b> A case report describes a 74-year-old man stable on nicardipine (50 mg twice daily) who developed a supratherapeutic sunitinib level (166 ng/mL), hypertension, and grade 2 hand-foot syndrome 8 days after starting sunitinib 50 mg daily.<sup>1</sup> Nicardipine was switched to amlodipine (5 mg daily) and sunitinib was maintained at 50 mg daily. Fourteen days later, hand-foot syndrome had improved to grade 1, blood pressure normalized, and his sunitinib concentration had returned to the therapeutic range (94 ng/mL).<sup>1</sup> No further sunitinib toxicities were noted during subsequent cycles.<sup>1</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but nicardipine inhibition of CYP3A4 mediated sunitinib metabolism may play a role.<sup>1</sup> However, because both nicardipine and amlodipine are considered weak CYP3A4 inhibitors,<sup>2,3,4,5</sup> the reason for the observed absence of an interaction with amlodipine is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Da Silva F, Thomas-Schoemann A, Huillard O, Goldwasser F, Blanchet B. Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker [published online April 26, 2016]. <i>Ann Oncol</i>. Doi: 10.1093/annonc/mdw182 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27117534\">[PubMed 27117534]</a></p>\n<p>2. Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. <i>Ann Pharmacother</i>. 2014;48(12):1580-1584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25280976\">[PubMed 25280976]</a></p>\n<p>3. Hooper DK, Fukuda T, Gardiner R, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. <i>Transplantation</i>. 2012;93(8):806-812. [PubMed 22491658]</p>\n<p>4. McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. <i>Drug Metab Dispos</i>. 2004;32(10):1083-1091. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15377640\">[PubMed 15377640]</a></p>\n<p>5. Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10545":"<p><b>Title</b> Omeprazole / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may decrease the serum concentration of Omeprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced omeprazole effectiveness if combined with darunavir/ritonavir. The effect of darunavir/cobicistat on omeprazole exposure is unknown.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the darunavir prescribing information, darunavir/ritonavir (600 mg/100 mg twice daily) decreased the omeprazole (40 mg single dose) AUC and maximum serum concentration 42% and 34%, respectively, in 12 healthy volunteers.<sup>1</sup> In a separate study of 17 healthy volunteers, omeprazole (20 mg daily x 4 days) had no effect on darunavir (given as darunavir/ritonavir 400 mg/100 mg twice daily) pharmacokinetics.<sup>2</sup> <br><br>Darunavir prescribing information states that when omeprazole and darunavir/ritonavir are combined, patients should be monitored for decreased omeprazole efficacy.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown and the effect of darunavir/cobicistat on omeprazole exposure is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016.</p>\n<p>2. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. <i>Antimicriob Agents Chemother</i>. 2007;51(3):958-961. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17210768\">[PubMed 17210768]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10546":"<p><b>Title</b> Ticagrelor / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased ticagrelor effects/toxicities (eg, bleeding) if combined with moderate CYP3A4 inhibitors. No dose adjustment of ticagrelor is recommended.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ticagrelor prescribing information, diltiazem (240 mg daily) increased the AUC and maximum serum concentration (Cmax) of ticagrelor 2.7-fold and 1.7-fold, respectively.<sup>1,2</sup> The Cmax of the active metabolite of ticagrelor was reduced 1.4-fold and the AUC was unchanged.<sup>1,2</sup><br><br>Ticagrelor product labeling states use with moderate CYP3A4 inhibitors may increase exposure to ticagrelor but no dose adjustment of ticagrelor is recommended.<sup>1,2</sup> In clinical trials of ticagrelor 33% of patients received the moderate CYP3A4 inhibitors diltiazem or verapamil.<sup>1</sup><br><br>The likely mechanism of this interaction is inhibition of CYP3A4-mediated ticagrelor metabolism by moderate CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brilinta (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca LP; September 2015.</p>\n<p>2. Brilinta (ticagrelor) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10547":"<p><b>Title</b> Aminoglycosides / Cephalothin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephalothin may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor closely for evidence of nephrotoxicity in patients who are receiving this combination.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The incidence of nephrotoxicity was higher with cephalothin plus an aminoglycoside than with ticarcillin plus an aminoglycoside (18% vs. 3%, respectively) in one comparison of these combinations.<sup>1</sup> Similarly, the incidence of nephrotoxicity was 21% to 30% with cephalothin plus gentamicin or tobramycin, but only 4% to 10% with methicillin plus gentamicin or tobramycin in another comparison.<sup>2</sup> Several other studies have also found significant associations between combinations of cephalothin and aminoglycosides and the incidence of nephrotoxicity.<sup>3,4,5</sup><br><br>In contrast, other studies have found that cephalothin treatment was not a significant risk factor for aminoglycoside associated nephrotoxicity,<sup>6</sup> and that there is no significant increase in nephrotoxicity among recipients of cephalothin plus an aminoglycoside as compared to those receiving another antibiotic (ie, cefamandole or ampicillin) plus an aminoglycoside.<sup>7,8</sup><br><br>Although the true increase in risk associated with this combination is unclear, the labeling for cephalothin products does acknowledge this potential risk and recommends caution with use of such a combination, particularly in patients with pre-existing renal function impairment.<sup>9,10,11</sup><br><br>The specific mechanism for this potential interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wade JC, Schimpff SC, Wiernik PH. Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer. <i>Arch Intern Med</i>. 1981;141(13):1789-1793. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6797359\">[PubMed 6797359]</a></p>\n<p>2. Wade JC, Smith CR, Petty BG, et al. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. <i>Lancet</i>. 1978;2(8090):604-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=80528\">[PubMed 80528]</a></p>\n<p>3. Prince RA, Ling MH, Hepler CD, et al. Factors associated with creatinine clearance changes following gentamicin therapy. <i>Am J Hosp Pharm</i>. 1980;37(11):1489-1495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211851\">[PubMed 7211851]</a></p>\n<p>4. Hansen MM, Kaaber K. Nephrotoxicity in combined cephalothin and gentamicin therapy. <i>Acta Med Scand</i>. 1977;201(5):463-467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=899868\">[PubMed 899868]</a></p>\n<p>5. Klastersky J, Hensgens C, Debusscher L. Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. <i>Antimicrob Agents Chemother</i>. 1975;7(5):640-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1096809\">[PubMed 1096809]</a></p>\n<p>6. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. <i>Ann Intern Med</i>. 1984;100(3):352-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6364908\">[PubMed 6364908]</a></p>\n<p>7. Brown AE, Quesada O, Armstrong D. Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease. <i>Antimicrob Agents Chemother</i>. 1982;21(4):592-594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7081979\">[PubMed 7081979]</a></p>\n<p>8. Palmblad J, Lonnqvist B. Combination of amikacin and either ampicillin or cephalotin as initial treatment of febrile neutropenic patients. <i>Acta Med Scand</i>. 1982;212(6):379-384. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6760676\">[PubMed 6760676]</a></p>\n<p>9. Keflin (cefalotin) [summary of product characteristics]. St. Leonards, New South Wales, Autralia: Aspen Pharmacare Australia Pty Ltd; October 2008.</p>\n<p>10. DBL (cephalothin) [summary of product characteristics]. Melbourne, Victoria, Autralia: Hospira Australia Pty Ltd; June 2012.</p>\n<p>11. Keflin (cephalothin) [summary of product characteristics]. Cosmopolis, Sao Paulo, Brazil: Antibiotics Brazil Ltda.; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10548":"<p><b>Title</b> Colistimethate / Cephalothin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephalothin may enhance the nephrotoxic effect of Colistimethate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cephalothin together with colistimethate.</p> \n<p><b>Discussion</b> The prescribing information for at least one cephalothin product cautions that concurrent use with colistimethate may increase the risk for renal dysfunction.<sup>1</sup> Specific data concerning this combination are not avaialble, but both cephalosporins and colistimethate have been independently associated with renal dysfunction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DBL (cephalothin) [summary of product characteristics]. Melbourne, Victoria, Autralia: Hospira Australia Pty Ltd; June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10549":"<p><b>Title</b> Cephalothin / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cephalothin together with a loop diuretic, with particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one cephalothin product cautions that concurrent use with the loop diuretics ethacrynic acid or furosemide may increase the risk for renal dysfunction.<sup>1</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>2</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DBL (cephalothin) [summary of product characteristics]. Melbourne, Victoria, Autralia: Hospira Australia Pty Ltd; June 2012.</p>\n<p>2. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10550":"<p><b>Title</b> Methotrexate / Cephalothin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephalothin may diminish the therapeutic effect of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to methotrexate closely if used together with cephalothin. Monitor for evidence of diminished methotrexate effectiveness.</p> \n<p><b>Discussion</b> The labeling for at least one cephalothin product states that cephalothin may decrease the effectiveness of methotrexate by inhibiting the cellular uptake of methotrexate.<sup>1</sup> An in vitro study showed that clinically relevant concentrations of cephalothin decreased the cellular uptake of methotrexate by 20%.<sup>2</sup> The mechanism and clinical significance of this interaction are both uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DBL (cephalothin) [summary of product characteristics]. Melbourne, Victoria, Autralia: Hospira Australia Pty Ltd; June 2012.</p>\n<p>2. Bender RA, Bleyer WA, Frisby SA, Oliverio VT. Alteration of methotrexate uptake in human leukemia cells by other agents. <i>Cancer Res</i>. 1975;35(5):1305-1308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1054621\">[PubMed 1054621]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10551":"<p><b>Title</b> Cephalothin / Agents with Antiplatelet Properties</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of bleeding or bruising with concurrent use of cephalothin and any antiplatelet agents.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The labeling for at least one cephalothin product states that the risk for bleeding may be increased with concurrent use of cephalothin and drugs that can inhibit platelet aggregation.<sup>1</sup> This warning appears to be a result of possible hypothrombinemia associatied with cephalosporins such as cephalothin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DBL (cephalothin) [summary of product characteristics]. Melbourne, Victoria, Autralia: Hospira Australia Pty Ltd; June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10552":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Pheniramine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pheniramine may enhance the anticholinergic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of this combination whenever possible. Monitor for enhanced or prolonged anticholinergic effects of pheniramine in patients receiving monoamine oxidase inhibitors (MAOIs). The manufacturer of at least one pheniramine product lists its use in combination with MAOIs as contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The concomitant use of a monoamine oxidase inhibitor (MAOI) with pheniramine may increase the duration or severity of anticholinergic effects compared with the use of either drug alone. Product labeling for at least one pheniramine product lists use with MAOIs as contraindicated due to the potential for these increased effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Avil (pheniramine) tablets [summary of product characteristics]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10553":"<p><b>Title</b> Anticholinergic Agents / Oxatomide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Oxatomide may enhance the anticholinergic effect of Anticholinergic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The oxatomide labeling recommends not using oxatomide together with anticholinergic drugs.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The oxatomide labeling says not to use oxatomide with an anticholinergic drug.<sup>1</sup> Specific data regarding such combinations are not available.<br><br>The mechanism for this labeled interaction is likely additive anticholinergic effects, as anticholinergic effects such as dry mount, urinary retention, and constipation have been reported with oxatomide use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tinset (oxatomide) tablet [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199303099. Accessed November 24, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10554":"<p><b>Title</b> Vitamin K Antagonists / Oxatomide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Oxatomide may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The oxatomide labeling recommends not using oxatomide together with a vitamin K antagonist (ie, coumarin-type) anticoagulant.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The oxatomide labeling recommends not using oxatomide together with a vitamin K antagonist (ie, coumarin-type) anticoagulant.<sup>1</sup> Specific data concerning such a combination are not available.<br><br>The specific mechanism for this labeled interaction is unknown. Oxatomide actions such as serotonin antagonism and inhibition of platelet activity could increase the risk of bleeding, and oxatomide being highly protein bound (98%) suggests it could displace anticoagulants from their protein binding sites.<sup>1</sup> However, whether any of these contribute to a clinically relevant interaction with vitamin K antagonists is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tinset (oxatomide) tablet [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199303099. Accessed November 24, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10555":"<p><b>Title</b> Aminoglycosides / Oxatomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Oxatomide may enhance the ototoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of ototoxicity with concurrent use of oxatomide and an aminoglycoside antibiotic.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The labeling for oxatomide states that concurrent use with aminoglycoside antibiotics may increase the risk for hearing disorders and ototoxicity.<sup>1</sup> The specific mechanism for this labeled interaction in unclear. Ear noise and hearing loss are listed as adverse effects of oxatomide.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tinset (oxatomide) tablet [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199303099. Accessed November 24, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10556":"<p><b>Title</b> Oxatomide / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxatomide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The oxatomide labeling states that strong CYP3A4 inhibitors such as ketoconazole or itraconazole may inhibit the metabolism of oxatomide.<sup>1</sup> The extent of this interaction and its clinical significance are unclear.<br><br>Both CYP3A4 and CYP2D6 have been shown, in vitro, to be involved in the metabolism of oxatomide.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tinset (oxatomide) tablet [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199303099. Accessed November 24, 2014.</p>\n<p>2. Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. <i>Biol Pharm Bull</i>. 2005;28(2):328-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15684493\">[PubMed 15684493]</a></p>\n<p>3. Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. <i>Biol Pharm Bull</i>. 2004;27(5):684-690. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15133245\">[PubMed 15133245]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10557":"<p><b>Title</b> Oxatomide / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Oxatomide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The oxatomide labeling states that cimetidine may inhibit the metabolism of oxatomide.<sup>1</sup> The extent of this interaction and its clinical significance are unclear.<br><br>Both CYP3A4 and CYP2D6 have been shown, in vitro, to be involved in the metabolism of oxatomide.<sup>2,3</sup> Cimetidine is a moderate CYP2D6 inhibitor and a weak CYP3A4 inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tinset (oxatomide) tablet [KR Prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199303099. Accessed November 24, 2014.</p>\n<p>2. Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. <i>Biol Pharm Bull</i>. 2005;28(2):328-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15684493\">[PubMed 15684493]</a></p>\n<p>3. Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. <i>Biol Pharm Bull</i>. 2004;27(5):684-690. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15133245\">[PubMed 15133245]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10558":"<p><b>Title</b> Velpatasvir / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of velpatasvir with a proton pump inhibitor is not recommended. If this combination is considered medically necessary, the labeling for sofosbuvir and velpatasvir recommends administering with food and 4 hours before omeprazole 20 mg. Use with other proton pump inhibitors has not been studied.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was 36% to 55% lower when administered with or 12 hours after omeprazole 20 mg daily to patients in a fasted state.<sup>1</sup> In fed patients, the valpatasvir AUC was 38% lower when given 2 hours after omeprazole 20 mg/day and 26% lower when given 4 hours before omeprazole 20 mg/day. In fed patients receiving higher-dose omeprazole (40 mg), the velpatasvir AUC was 53% lower when given 4 hours before omeprazole.<br><br>Consistent with these findings, the labeling for sofosbuvir and velpatasvir recommends avoiding coadministration with proton pump inhibitors when possible.<br><br>The mechanism for this interaction appears to be impaired solubility of velpatasvir at higher gastric pH values, leading to decreased absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10559":"<p><b>Title</b> Velpatasvir / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Avoid high doses of H2-antagonists with velpatasvir. Limit doses to those comparable to or lower than famotidine 40 mg twice daily.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Velpatasvir can be administered with H2-antagonists at doses comparable to or lower than famotidine 40 mg twice daily. With any concurrent use, monitor for evidence of decreased clinical response.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was 15% to 19% lower when administered with or 12 hours after famotidine 40 mg (single dose) in a study of 60 subjects.<sup>1</sup> These effects are less substantial than those seen with the proton pump inhibitor omeprazole, where the velpatasvir AUC was 26% to 55%.<sup>1</sup><br><br>The mechanism for this interaction appears to be impaired solubility of velpatasvir at higher gastric pH values, leading to decreased absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10560":"<p><b>Title</b> Velpatasvir / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of velpatasvir and antacids by at least 4 hours.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this interaction are not available, but data with the acid-lowering proton pump inhibitor omeprazole and with the H2-antagonist famotidine show a 26% to 55% lower and a 15% to 19% lower velpatasvir AUC, respectively, when administered with these agents.<sup>1</sup><br><br>The mechanism for this interaction appears to be impaired solubility of velpatasvir at higher gastric pH values, leading to decreased absorption. Separating administration by at least 4 hours should allow the gastric pH-raising actions of the antacid to wear-off prior to velpatasvir administration, lessening the potential significance of the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10561":"<p><b>Title</b> Velpatasvir / CYP2B6 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of sofosbuvir and velpatasvir with moderate or strong inducers of p-glycoprotein, CYP2B6, CYP2C8, or CYP3A4 is not recommended.</p>\n<div>\n <p><b>CYP2B6 Inducers (Moderate) Interacting Members</b> CarBAMazepine, Efavirenz, Nevirapine, RifAMPin, Ritonavir</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was an average of 82% lower with concurrent use of rifampin (600 mg/day), which is a strong inducer of CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein.<sup>1,2</sup> The velpatasvir AUC was an average of 53% lower with the combination product efavirenz/emtricitabine/tenofovir disoproxil fumarate, which likely reflects the moderate CYP3A4- and moderate CYP2B6-inducing actions of efavirenz.<sup>1</sup><br><br>CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein all appear to participate in velpatasvir disposition and metabolism,<sup>1,2</sup> and induction of one or more of these pathways would likely decrease velpatasvir concentrations to a potentially significant degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10563":"<p><b>Title</b> Velpatasvir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of sofosbuvir and velpatasvir with moderate or strong inducers of p-glycoprotein, CYP2B6, CYP2C8, or CYP3A4 is not recommended.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was an average of 82% lower with concurrent use of rifampin (600 mg/day), which is a strong inducer of CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein.<sup>1,2</sup> The velpatasvir AUC was an average of 53% lower with the combination product efavirenz/emtricitabine/tenofovir disoproxil fumarate, which likely reflects the moderate CYP3A4- and moderate CYP2B6-inducing actions of efavirenz.<sup>1</sup><br><br>CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein all appear to participate in velpatasvir disposition and metabolism,<sup>1,2</sup> and induction of one or more of these pathways would likely decrease velpatasvir concentrations to a potentially significant degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10564":"<p><b>Title</b> Velpatasvir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of sofosbuvir and velpatasvir with moderate or strong inducers of p-glycoprotein, CYP2B6, CYP2C8, or CYP3A4 is not recommended.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was an average of 82% lower with concurrent use of rifampin (600 mg/day), which is a strong inducer of CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein.<sup>1,2</sup> The velpatasvir AUC was an average of 53% lower with the combination product efavirenz/emtricitabine/tenofovir disoproxil fumarate, which likely reflects the moderate CYP3A4- and moderate CYP2B6-inducing actions of efavirenz.<sup>1</sup><br><br>CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein all appear to participate in velpatasvir disposition and metabolism,<sup>1,2</sup> and induction of one or more of these pathways would likely decrease velpatasvir concentrations to a potentially significant degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10565":"<p><b>Title</b> Velpatasvir / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of sofosbuvir and velpatasvir with moderate or strong inducers of p-glycoprotein, CYP2B6, CYP2C8, or CYP3A4 is not recommended.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The velpatasvir AUC was an average of 82% lower with concurrent use of rifampin (600 mg/day), which is a strong inducer of CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein.<sup>1,2</sup> The velpatasvir AUC was an average of 53% lower with the combination product efavirenz/emtricitabine/tenofovir disoproxil fumarate, which likely reflects the moderate CYP3A4- and moderate CYP2B6-inducing actions of efavirenz.<sup>1</sup><br><br>CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein all appear to participate in velpatasvir disposition and metabolism,<sup>1,2</sup> and induction of one or more of these pathways would likely decrease velpatasvir concentrations to a potentially significant degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10566":"<p><b>Title</b> Topotecan / Velpatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Velpatasvir may increase the serum concentration of Topotecan. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of sofosbuvir and velpatasvir with topotecan is not recommended.</p> \n<p><b>Discussion</b> The labeling for sofosbuvir and velpatasvir states that concurrent use of topotecan is not recommended.<sup>1</sup> Though not specified, the likely mechanism for this interaction is inhibition of BCRP (aka ABCG2) by valpatasvir.<br><br>Combined administration of oral topotecan with elacridar [investigational inhibitor of p-glycoprotein and breast cancer resistance protein (BCRP/ABCG2)] resulted in a significant increase in topotecan bioavailability, AUC, and maximum plasma concentration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Hycamtin (topotecan) capsules [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10567":"<p><b>Title</b> Digoxin / Velpatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Velpatasvir may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor digoxin concentrations more closely following initiation or withdrawal of velpatasvir, and monitor for any clinical evidence of digoxin toxicity or adverse effects.</p> \n<p><b>Discussion</b> The digoxin AUC was an average of 34% higher with concurrent velpatasvir in a study of 21 subjects who received velpatasvir 100 mg/day for 5 days and a single dose of digoxin (0.25 mg).<sup>1</sup><br><br>The likely mechanism for this interaction is inhibition of digoxin p-glycoprotein efflux by velpatasvir, which appears to be a p-glycoprotein inhibitor.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p>2. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10568":"<p><b>Title</b> Tenofovir Disoproxil Fumarate / Velpatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Velpatasvir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of tenofovir disoproxil fumarate adverse effects.</p> \n<p><b>Discussion</b> The tenofovir disoproxil fumarate (DF) AUC was increased 1.3- to 1.8-fold with concurrent velpatasvir in several studies examining the use of velpatasvir with different tenofovir DF-containing products.<sup>1,2</sup><br><br>The specific mechanism for this apparent interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10569":"<p><b>Title</b> Rosuvastatin / Velpatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Velpatasvir may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit rosuvastatin to no more than 10 mg/day if used together with velpatasvir. Monitor closely for evidence of rosuvastatin adverse effects with use of this combination.</p> \n<p><b>Discussion</b> The rosuvastatin AUC was an average of 2.7-fold higher with concurrent use of velpatasvir in a study of 18 subjects who received a single dose of rosuvastatin 10 mg with velpatasvir 100 mg/day.<sup>1,2</sup><br><br>The likely mechanism of this interaction is inhibition of rosuvastatin BCRP and/or OATP transport by velpatasvir, which has been shown to inhibit BCRP, OATP1B1, and OATP1B3.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10570":"<p><b>Title</b> AtorvaSTATin / Velpatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Velpatasvir may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for atorvastatin adverse effects or toxicity with use of this combination.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but data with rosuvastatin, which, like atorvastatin, is a substrate for BCRP and/or OATP, suggests an interaction is likely.<br><br>The rosuvastatin AUC was an average of 2.7-fold higher with concurrent use of velpatasvir in a study of 18 subjects who received a single dose of rosuvastatin 10 mg with velpatasvir 100 mg/day.<sup>1,2</sup><br><br>The likely mechanism of this predicted interaction is inhibition of atorvastatin BCRP and/or OATP transport by velpatasvir, which has been shown to inhibit BCRP, OATP1B1, and OATP1B3.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10584":"<p><b>Title</b> Quinolones / Nadifloxacin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nadifloxacin may enhance the adverse/toxic effect of Quinolones. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of topical nadifloxacin in patients receiving systemic quinolone antibiotics.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> Nadifloxacin product labeling states that although the absorption of nadifloxacin through human skin is very low, use with other quinolones should be avoided due to the risk of additive toxicities.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nadifloxacin [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200706607. Accessed May 1, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10585":"<p><b>Title</b> Pindolol / Monoamine Oxidase Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The Canadian labeling for pindolol states that use with a monoamine oxidase inhibitor is not recommended. This specific recommendation is not included in the U.S. labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended. This specific recommendation is not included in the U.S. pindolol labeling.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Canadian pindolol labeling states that use of this combination may result in an increased risk of hypotension, orthostatic hypotension, bradycardia, or heart failure, and that the combination is not recommended.<sup>1</sup> Due to the long duration of monoamine oxidase (MAO) inhibitor actions, this increased risk may persist for up to 14 days after discontinuation of a MAO inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Visken (pindolol) [prescribing information]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10586":"<p><b>Title</b> Udenafil / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of udenafil and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 3 days) increased the udenafil (100 mg single dose) AUC and maximum serum concentration (Cmax) 3.2-fold and 1.9-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the udenafil product labeling, ketoconazole (400 mg) increased the udenafil (100 mg) AUC and Cmax 2.1-fold and 1.85-fold, respectively.<sup>2</sup><br><br>Udenafil product labeling states that due to the risk for increased udenafil exposure and effects, concomitant use with strong CYP3A4 inhibitors is not recommended.<sup>2</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4-mediated udenafil metabolism by strong CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Chung YJ, Kim BH, et al. Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. <i>Br J Clin Pharmacol</i>. 2010;69(3):307-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233203\">[PubMed 20233203]</a></p>\n<p>2. Udenafil 100/200 mg tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200500258. Accessed September 22, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10587":"<p><b>Title</b> Udenafil / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased udenafil effects/toxicities if combined with moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> No clinical studies have evaluated the use of udenafil and moderate CYP3A4 inhibitors. However, in a pharmacokinetic study of 12 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 3 days) increased the udenafil (100 mg single dose) AUC and maximum serum concentration (Cmax) 3.2-fold and 1.9-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the udenafil product labeling, ketoconazole (400 mg) increased the udenafil (100 mg) AUC and Cmax 2.1-fold and 1.85-fold, respectively.<sup>2</sup><br><br>Udenafil product labeling states that concomitant use of udenafil and CYP3A4 inhibitors may result in increased udenafil exposure and effects.<sup>2</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4-mediated udenafil metabolism by CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Chung YJ, Kim BH, et al. Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. <i>Br J Clin Pharmacol</i>. 2010;69(3):307-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233203\">[PubMed 20233203]</a></p>\n<p>2. Udenafil 100/200 mg tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200500258. Accessed September 22, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10588":"<p><b>Title</b> Udenafil / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased udenafil effects if combined with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the effect of strong CYP3A4 inducers on udenafil exposure, but since CYP3A4 is responsible for the majority of udenafil metabolism, concomitant use is expected to reduce udenafil exposure and effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Udenafil 100/200 mg tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200500258. Accessed September 22, 2014.</p>\n<p>2. Ji HY, Lee HW, Kim HH, et al. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. <i>Xenobiotica</i>. 2004;34(11-12):973-982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15801542\">[PubMed 15801542]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10589":"<p><b>Title</b> Vitamin E (Systemic) / Glucomannan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Glucomannan may decrease the serum concentration of Vitamin E (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 11 subjects, coadministration of glucomannan (3.9 g konjac mannan, manufactured by Shimizu Chemical Industries Co Ltd) reduced the increase from baseline in serum vitamin E concentrations following a single oral dose of tocopherol acetate (500 mg) at several time points (1, 3, 8, and 12 hours after dosing, but not at 5 or 24 hours) in healthy volunteers (n = 6) but not at any time points in diabetic patients (n = 5).<sup>1</sup><br><br>The mechanism and potential clinical significance of the interaction between these agents are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doi K, Matsuura M, Kawara A, Tanaka T, Baba S. Influence of dietary fiber (konjac mannan) on absorption of vitamin B12 and vitamin E. <i>Tohoku J Exp Med</i> 1983;141(suppl):677-681. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6096987\">[PubMed 6096987]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10590":"<p><b>Title</b> Pindolol / Flecainide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Flecainide may enhance the bradycardic effect of Pindolol. The negative inotropic effects of Pindolol may also be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of excessive bradycardia, heart block, or heart failure with use of this combination.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the Canadian labeling for pindolol states that use with flecainide may potentiate the effects on atrial conduction and the negative inotropic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10591":"<p><b>Title</b> Pindolol / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Pindolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The pindolol AUC has been shown to be increased by up to an average of 30% with concurrent cimetidine.<sup>1,2</sup> The clinical significance of this is uncertain.<br><br>The specific mechanism for this interaction is not clear. Cimetidine is a relatively weak inhibitor of several individual cytochrome P450 enzymes, suggesting that cimetidine may be inhibiting pindolol metabolism.<sup>3</sup> Cimetidine has also been shown to inhibit the renal clearance of pindolol,<sup>4</sup> and such an effect could also explain the observed increase in pindolol concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6146340\">[PubMed 6146340]</a></p>\n<p>2. Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849789\">[PubMed 6849789]</a></p>\n<p>3. Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016.</p>\n<p>4. Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1563208\">[PubMed 1563208]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10592":"<p><b>Title</b> MetFORMIN / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: This combination is not recommended in patients with impaired renal or hepatic function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of lactic acidosis with use of this combination. Respiratory distress, somnolence, and non-specific abdominal distress or worsening renal function are listed as examples of specific signs and symptoms that may be indicative of possible lactic acidosis. Use of this combination in patients with impaired renal or hepatic function is not recommended.</p> \n<p><b>Discussion</b> The labeling for products containing the combination of ombitasvir, paritaprevir, and ritonavir state that concurrent use with metformin should be accompanied by specific monitoring for lactic acidosis and that concomitant use in patients with impaired renal or hepatic function is not recommended.<sup>1,2</sup> No specific information concerning the use of such combinations are provided.<br><br>The specific mechanism for this listed interaction is unclear. It does not appear that metformin concentrations are expected to be increased with this combination, which suggests this is a suspected pharmacodynamic interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10593":"<p><b>Title</b> MetFORMIN / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: This combination is not recommended in patients with impaired renal or hepatic function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of lactic acidosis with use of this combination. Respiratory distress, somnolence, and non-specific abdominal distress or worsening renal function are listed as examples of specific signs and symptoms that may be indicative of possible lactic acidosis. Use of this combination in patients with impaired renal or hepatic function is not recommended.</p> \n<p><b>Discussion</b> The labeling for products containing the combination of ombitasvir, paritaprevir, and ritonavir state that concurrent use with metformin should be accompanied by specific monitoring for lactic acidosis and that concomitant use in patients with impaired renal or hepatic function is not recommended.<sup>1,2</sup> No specific information concerning the use of such combinations are provided.<br><br>The specific mechanism for this listed interaction is unclear. It does not appear that metformin concentrations are expected to be increased with this combination, which suggests this is a suspected pharmacodynamic interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10594":"<p><b>Title</b> Carisoprodol / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of Carisoprodol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced carisoprodol effectiveness. An increased carisoprodol dose may be necessary.</p> \n<p><b>Discussion</b> The carisoprodol AUC was an average of 38% lower, and the AUC of its metabolite meprobamate was an average of 9% higher, with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 14 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10595":"<p><b>Title</b> Carisoprodol / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of Carisoprodol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced carisoprodol effectiveness. An increased carisoprodol dose may be necessary.</p> \n<p><b>Discussion</b> The carisoprodol AUC was an average of 38% lower, and the AUC of its metabolite meprobamate was an average of 9% higher, with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 14 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10596":"<p><b>Title</b> Cyclobenzaprine / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of Cyclobenzaprine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced cyclobenzaprine effectiveness. An increased cyclobenzaprine dose may be necessary.</p> \n<p><b>Discussion</b> The cyclobenzaprine AUC was an average of 40% lower with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 14 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10597":"<p><b>Title</b> Cyclobenzaprine / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of Cyclobenzaprine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced cyclobenzaprine effectiveness. An increased cyclobenzaprine dose may be necessary.</p> \n<p><b>Discussion</b> The cyclobenzaprine AUC was an average of 40% lower with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 14 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10598":"<p><b>Title</b> DiazePAM / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced diazepam effectiveness. An increased diazepam dose may be necessary.</p> \n<p><b>Discussion</b> The diazepam AUC was an average of 22% lower, and the AUC of the active nordiazepam metabolite was an average of 44% lower, with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 13 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10599":"<p><b>Title</b> DiazePAM / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced diazepam effectiveness. An increased diazepam dose may be necessary.</p> \n<p><b>Discussion</b> The diazepam AUC was an average of 22% lower, and the AUC of the active nordiazepam metabolite was an average of 44% lower, with concurrent ombitasvir, paritaprevir, ritonavir, and dasabuvir in a study of 13 subjects.<sup>1,2</sup> The specific mechanism for and significance of this apparent interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir, paritaprevir, and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}